Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says

biogen
Biogen released new data on Spinraza at the World Muscle Society's annual congress over the weekend. i(Biogen)

Biogen’s spinal muscular atrophy med Spinraza hit the market running after its launch, helping fuel growth at the drugmaker as its MS franchise faced a slowdown. Now, the company is touting an interim analysis showing that infants with SMA can benefit "dramatically" from the drug if they’re treated before symptoms develop.

The Nurture study is testing Spinraza in 25 patients genetically diagnosed with the disease and treated before symptoms developed. At an interim analysis in May 2018, all patients were alive, and none required tracheostomy or permanent ventilation. The patients were 14 months or older at the time of the analysis.

Plus, 88% percent of the patients were able to walk, either with assistance or independently, and all were able to sit without support. In a note, Evercore ISI analyst Josh Schimmer said the results were "pretty amazing."

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

Wildon Farwell, M.D., Biogen senior medical director of clinical development, said in a statement the data show that “early diagnosis and treatment with Spinraza has the potential to dramatically change the course of SMA."

RELATED: The top 10 drug launches of 2017Spinraza

“This is the longest available span of data on infants with SMA who began treatment in a presymptomatic period and indicates that children treated early with Spinraza can achieve motor milestones they would likely not attain without treatment,” Farwell added.

Biogen launched Spinraza after an approval in late 2016, and the drug quickly captured headlines for its price of $750,000 for the first year and $375,000 annually after that. Despite some concern about the price, the drug has far surpassed early expectations, leaping out to $884 million in sales during its first full year on the market.

RELATED: Biogen's Spinraza zooms through blockbusterland, but analysts are fixated on Alzheimer's data

As of this summer, the drug has won approval in at least 24 countries. More than 5,000 patients were taking Spinraza as of June, including those in an expanded access program, clinical trials and a postmarketing study, according to Biogen.

Biogen presented the new Spinraza data at the World Muscle Society’s annual congress in Mendoza, Argentina.

Suggested Articles

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.